|
Affymax and Takeda Announce Phase 3 Trials Meet Primary Endpoints for ... - MarketWatch (press release) |
 |
|
MarketWatch (press release)In a subgroup analysis of CSE events in the EMERALD studies in maintenance treatment of anemia in dialysis patients, the frequency of CSE events was ...Piper Jaffray Downgrades Affymax (AFFY) to Underweight; Disappointing Hematide ... StreetInsider.com (subscription)Affymax shares plunge on PhIII cardio issues for Hematide FierceBiotechAffymax' Anemia Drug Meets Goals Of Phase III Trials; Shares Plunge On Safety ...
|